Q2 2026 13F · SEC CIK 1618205

Birchview Capital, LP

Wealth managerFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $213.8M
Reported positions: 72
Top holdings a year, 3 yrs: +3.4%
Assets under management: $239.1M

Birchview Capital, LP is a wealth manager that reported 72 positions worth $213.8M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Kla Corp (KLAC, 25.2%), Bristol-Myers Squibb Co (BMY, 8.0%), Lam Research Corp (LRCX, 7.1%). A portfolio copying its top holdings returned 3.4% a year over the last 3 years, against 22.3% for the S&P 500.

Birchview Capital, LP holdings largest 50 of 72 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Birchview Capital, LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
KLACKla Corp	25.2%	16.7%	178,471	+797.6%	$53.8M
BMYBristol-Myers Squibb Co	8.0%	10.6%	297,243	-2.9%	$17.1M
LRCXLam Research Corp	7.1%	4.4%	35,000	-2.8%	$15.2M
NTLAIntellia Therapeutics Inc	3.2%	3.3%	385,900	-13.4%	$6.8M
SLDBSolid Bioscience Inc.	3.1%	2.6%	666,196	+6.4%	$6.7M
BDSXBiodesix Inc	3.0%	2.4%	286,804	+0.0%	$6.5M
STOKStoke Therapeutics Inc	2.7%	3.9%	178,110	-15.2%	$5.8M
OVVOvintiv Inc Com	2.6%	3.6%	107,500	+0.0%	$5.7M
NKTRNektar Therapeutics	2.6%	1.3%	81,000	+161.3%	$5.7M
CORTCorcept Therapeutics Inc	2.3%	1.1%	57,200	+21.2%	$5.0M
NBIXNeurocrine Biosciences Inc	2.1%	2.0%	27,190	+0.0%	$4.6M
PRTAProthena Corp PLC Shs	2.1%	2.5%	449,019	+0.0%	$4.4M
ACADAcadia Pharmaceuticals Inc	2.0%	2.2%	171,000	+0.0%	$4.3M
PTGXProtagonist Therapeutics Inc	2.0%	2.1%	35,018	+0.1%	$4.3M
CMPXCompass Therapeutics Inc	1.7%	4.4%	1,675,000	+14.3%	$3.7M
RLMDRelmada Therapeutics Inc	1.3%	1.6%	408,100	-0.3%	$2.8M
ALKSAlkermes PLC	1.2%	1.0%	50,000	+0.0%	$2.6M
HALOHalozyme Therapeutics Inc	1.2%	0.4%	33,251	+229.2%	$2.6M
CLDXCelldex Therapeutics Inc New	1.2%	1.3%	69,900	-0.3%	$2.6M
CYTKCytokinetics	1.2%	1.1%	30,000	+0.0%	$2.6M
OLMAOlema Pharmaceuticals Inc	1.2%	1.9%	199,000	-9.1%	$2.5M
VERAVera Therapeutics Inc Class A	1.2%	1.0%	57,758	+31.3%	$2.5M
UTHRUnited Therapeutics Corp Del	1.1%	1.5%	4,506	+0.1%	$2.4M
ZBIOZenas Biopharma Inc	1.1%	0.8%	93,601	+33.7%	$2.4M
QUREUniqure NV	1.1%	0.9%	50,697	-49.7%	$2.3M
PACBPacific Biosciences Calif in	1.1%	1.1%	1,350,000	-10.0%	$2.3M
ABVXAbivax SA	1.1%	—	17,000	—	$2.3M
VIRVir Biotechnology Inc	1.0%	—	220,000	—	$2.2M
BIIBBiogen Inc	0.9%	0.5%	9,000	+80.0%	$1.9M
EQTEqt Corp	0.9%	1.3%	34,619	+0.0%	$1.8M
BIOABioage Labs Inc	0.8%	—	69,000	—	$1.7M
TVTXTravere Therapeutics Inc	0.8%	0.5%	29,000	-0.7%	$1.6M
QDELQuidelortho Corp	0.7%	0.8%	89,377	+8.3%	$1.6M
AXSMAxsome Therapeutics, Inc.	0.7%	0.6%	6,000	+0.0%	$1.5M
FHTXFoghorn Therapeutics Inc	0.6%	0.8%	281,937	+0.1%	$1.4M
BCYCBicycle Therapeutics PLC	0.6%	1.2%	313,616	-32.4%	$1.3M
GPCRStructure Therapeutics F Unspo	0.6%	2.7%	24,000	-76.0%	$1.3M
XENEXenon Pharmaceuticals Inc	0.6%	0.7%	21,032	+0.2%	$1.3M
NVONovo-Nordisk A S	0.5%	—	24,000	—	$1.2M
FCXFreeport Mcmoran Inc	0.5%	0.6%	18,035	-0.0%	$1.1M
IMNMImmunome Inc	0.5%	0.6%	50,000	+0.0%	$1.1M
PHVSPharvaris N V	0.5%	0.5%	29,847	+0.0%	$1.0M
HROWHarrow Inc	0.5%	0.5%	24,000	+0.0%	$1.0M
ADAGAdagene Inc	0.5%	—	240,000	—	$1.0M
24477V105Definium Therapeutics Inc	0.4%	—	20,000	—	$941K
SLNSilence Therapeutics PLC	0.4%	—	71,218	—	$782K
BBIOBridgebio Pharma Inc	0.3%	0.4%	8,741	+0.6%	$651K
FDMT4d Molecular Therapeutics in	0.3%	—	48,505	—	$645K
URGNUrogen Pharma Ltd	0.3%	—	16,487	—	$607K
PHATPhathom Pharmaceuticals Inc Com	0.3%	1.2%	55,000	-71.8%	$597K

What Birchview Capital, LP bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +7.8% /yr; S&P 500 +11.7%
3 years: +3.4% /yr; S&P 500 +22.3%
5 years: -5.6% /yr; S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$213.8M	72
Q1 2026	$175.7M	73
Q4 2025	$170.8M	68
Q3 2025	$132.4M	69
Q2 2025	$100.7M	71
Q1 2025	$115.2M	68
Q4 2024	$122.7M	68
Q3 2024	$115.2M	61
Q2 2024	$108.0M	60
Q1 2024	$122.5M	59
Q4 2023	$127.5M	58
Q3 2023	$117.5M	51

Questions about Birchview Capital, LP's portfolio

What stocks does Birchview Capital, LP own?

Birchview Capital, LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 72 positions worth $213.8M. The largest are Kla Corp (KLAC) at 25.2%, Bristol-Myers Squibb Co (BMY) at 8.0%, Lam Research Corp (LRCX) at 7.1%, Intellia Therapeutics Inc (NTLA) at 3.2% and Solid Bioscience Inc. (SLDB) at 3.1%.

What did Birchview Capital, LP buy last quarter?

In Q2 2026, Birchview Capital, LP added Kla Corp (KLAC) (+797.6% shares), Halozyme Therapeutics Inc (HALO) (+229.2% shares) and Nektar Therapeutics (NKTR) (+161.3% shares), compared with its Q1 2026 filing.

What did Birchview Capital, LP sell last quarter?

In Q2 2026, Birchview Capital, LP cut from its top 50 Ocular Therapeutix Inc (OCUL), cut from its top 50 Novocure Ltd (NVCR), cut from its top 50 Compass Pathways PLC (CMPS), cut from its top 50 enGene Holdings Inc. (ENGN), cut from its top 50 Ultragenyx Pharmaceutical in (RARE), Structure Therapeutics F Unspo (GPCR) (-76.0% shares), Phathom Pharmaceuticals Inc Com (PHAT) (-71.8% shares) and Uniqure NV (QURE) (-49.7% shares), compared with its Q1 2026 filing.

How has Birchview Capital, LP's portfolio performed?

A portfolio copying Birchview Capital, LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +3.4% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +7.8% against +11.7%. Over 5 years: -5.6% a year against +10.6%.

When is Birchview Capital, LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Birchview Capital, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Birchview Capital, LP manage?

Birchview Capital, LP reported $239.1M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $213.8M.